William Blair & Company’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $586K | Sell |
4,664
-1,550
| -25% | -$195K | ﹤0.01% | 1048 |
|
|
2025
Q1 | $687K | Sell |
6,214
-242
| -4% | -$26.8K | ﹤0.01% | 990 |
|
|
2024
Q4 | $881K | Buy |
6,456
+12
| +0.2% | +$1.64K | ﹤0.01% | 940 |
|
|
2024
Q3 | $742K | Sell |
6,444
-1,383
| -18% | -$159K | ﹤0.01% | 997 |
|
|
2024
Q2 | $1.08M | Sell |
7,827
-772
| -9% | -$106K | ﹤0.01% | 847 |
|
|
2024
Q1 | $1.19M | Buy |
8,599
+481
| +6% | +$66.3K | ﹤0.01% | 814 |
|
|
2023
Q4 | $1.07M | Sell |
8,118
-562
| -6% | -$74K | ﹤0.01% | 836 |
|
|
2023
Q3 | $977K | Sell |
8,680
-5,585
| -39% | -$628K | ﹤0.01% | 845 |
|
|
2023
Q2 | $1.35M | Sell |
14,265
-297,485
| -95% | -$28.1M | ﹤0.01% | 756 |
|
|
2023
Q1 | $31.6M | Buy |
311,750
+237,264
| +319% | +$24M | 0.13% | 150 |
|
|
2022
Q4 | $8.9M | Buy |
74,486
+63,184
| +559% | +$7.55M | 0.04% | 313 |
|
|
2022
Q3 | $1.2M | Buy |
11,302
+170
| +2% | +$18.1K | 0.01% | 760 |
|
|
2022
Q2 | $1.09M | Buy |
11,132
+602
| +6% | +$58.7K | ﹤0.01% | 823 |
|
|
2022
Q1 | $987K | Sell |
10,530
-4,807
| -31% | -$451K | ﹤0.01% | 927 |
|
|
2021
Q4 | $1.31M | Sell |
15,337
-4,740
| -24% | -$404K | ﹤0.01% | 863 |
|
|
2021
Q3 | $1.93M | Buy |
20,077
+162
| +0.8% | +$15.5K | 0.01% | 715 |
|
|
2021
Q2 | $1.94M | Buy |
19,915
+248
| +1% | +$24.1K | 0.01% | 714 |
|
|
2021
Q1 | $1.91M | Sell |
19,667
-10,562
| -35% | -$1.03M | 0.01% | 706 |
|
|
2020
Q4 | $2.9M | Buy |
+30,229
| New | +$2.9M | 0.01% | 556 |
|